Outcomes from pneumococcal meningitis (PM) are worse than meningococcal meningitis (MM), particularly in settings with high HIV-1 prevalence, but the reasons are unknown. We compared inflammatory responses between PM and MM in Malawian adults.
Text Background
In most areas of the world, community-acquired acute bacterial meningitis (ABM) in adolescents and young adults is predominately caused by one of two bacterial pathogens, Streptococcus pneumoniae or Neisseria meningitidis [1, 2] . Although vaccination has impacted on ABM incidence in adults in well-resourced settings, in LMICs beyond the Sahel region in Africa, where both HIV infection and an intense force of bacterial carriage mean ABM remains a significant infectious disease [3, 4] .
ABM caused by these pathogens is frequently indistinguishable at the bedside, but the clinical course is markedly different [5] . In LMICs case fatality rates (CFR) for pneumococcal meningitis (PM) reach 70%, compared to 5-10% for meningococcal meningitis (MM) [4, [6] [7] [8] [9] . In all settings, 20-30% of survivors of PM experience complications including deafness, stroke and paralysis [2] . Estimates of years of life lost to disability (YLD) from PM are over twice those of MM [4, 10] . The two pathogens both have well-described host-pathogen interactions in animal models of meningitis and risk factors for acquisition in humans, but why outcomes differ markedly between PM and MM is not known [11] [12] [13] [14] .
Bacterial invasion into the CSF in ABM triggers a rapid-onset, localised inflammatory response, with resulting in migration of white cells across the blood-brain barrier to provide innate and adaptive immune responses in CSF to kill bacteria [15] . Both S.pneumoniae and N.meningitidis have differing mechanisms to avoid complementmediated killing and phagocytosis in CSF [14, 16] . Of the small number of prospective clinical studies comparing the inflammatory response between the two pathogens, only complement activity [17, 18] , and subtle differences between CSF cytokines [19] [20] [21] have been reported. To support development of new adjunctive treatments for ABM, we tested the hypothesis that differences in the cellular inflammatory response may differ in HIV-1 co-infected adults with ABM, accounting for differences in clinical outcomes in a high HIV prevalence setting in sub-Saharan Africa. We compared the inflammatory response in Malawian adults between cases of proven PM or MM using clinical, immunological and transcriptomic profiling.
Methods

Participants
Prospectively collected clinical data from adults and adolescents presenting to CSF and blood samples were collected prior to administration of parenteral ceftriaxone. Clinical data were recorded on admission to hospital, repeat LP was performed for therapeutic monitoring at 48 hours in most participants recruited to clinical trials [24, 25] . Mortality was reported to 6 weeks [23].
Procedures
Routine CSF microscopy, cell count, and CSF culture was done at the MalawiLiverpool-Wellcome Trust Clinical Research Programme laboratory in Blantyre, Malawi as previously described [23] . Culture negative samples were screened using a multiplex PCR for S. pneumoniae, N. meningitidis and Haemophilus influenzae type b (Hib) (Fast-Track Diagnostics, Luxemburg). CSF cytokines were measured by bead array, as described [26] . CSF and whole blood for transcriptional profiling were collected in blood PAX-gene® (Pre-AnalytiX, Qiagen, USA) tubes, incubated for 4 hours at room temperature, and stored at -80 degrees°C. All patients were HIV tested using point-of care Genie™ HIV1&2 test kits (BioRad, USA).
RNA was extracted from blood and CSF using the PAXgene® Blood miRNA kit (PreAnalytix, Qiagen, USA), quantified and RIN scores calculated using RNA Tapestation 4200® (Agilent, USA) and Nanodrop® (Thermoscientific, USA).
Extracted RNA samples with RIN >7 underwent library preparation for polyA tailed mRNA with a RNA concentration of >1ng/1ul using with Kapa RNA hyperPrep kit (Roche), followed by 75 cycles of Next-generation sequencing with NextSeq® (Illumina®, USA).
Bioinformatics and statistical analysis
Alpha <0.05 denoted statistical significance for all analyses, Mann-Whitney U tests were used on skewed data, and student's t test for normally distributed data. 95% confidence intervals were presented for Odds Ratios. Logistic regression between clinical outcomes and risk factors was used to model associations while controlling for confounding factors. 95% confidence intervals presented for Odds Ratios.
Fisher's exact test was used to compare categorical variables. Graphical correlations were analysed using goodness of fit, statistical correlations calculated using Spearman's test. Data were analysed in SPSS version 24 (IBM Statistics USA®) and GraphPad PRISM® version 7.0. Sequencing data quality was assessed using the FASTQC toolkit (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), sequenced cDNA libraries mapped at the transcript and gene levels to the human genome (assembly GRCh38) using Salmon v0.8.2
(http://salmon.readthedocs.io/en/latest/index.html).
The R package DESeq2 was used to test for differential gene expression. Data were expressed as log 2 normalised gene counts, and FDR corrected p-values <0.05 used to test for significance. Network graphs of differentially expressed genes were generated using R package XGR (http://galahad.well.ox.ac.uk:3020/subneter/genes) and Gephi (https://gephi.org/),.
Ethics
All participants or nominated guardians gave written informed consent for inclusion in the participating studies. Ethical approval for the transcriptomics study was granted 
Results
Clinical data
We compared clinical details of proven PM cases (n=440) and MM cases (n=27) in the MMD (Supplementary Figure 1) Figure 1A ).
In a sub-set of patients who had CSF cytokine profiling, TNF alpha, IL-8 (CXCL8) and IL-1 in CSF were significantly higher from cases of PM (n=66) compared to MM (n=11) on admission to hospital ( Figure 1C ) ( Table 1 ). All CSF cytokines were lower at 48 hours ( Figure 1B ). CSF WCC did not correlate with any of tested CSF cytokines, including IL-8 (CXCL8) (S. Figure 2A&B ). There was little evidence of systemic cytokine responses in blood (S. Figure 3 
CSF and blood transcriptomics
To examine the wider inflammatory response using transcriptomics between cases of PM and MM, we undertook paired CSF and blood transcriptional profiling using RNAseq (Supplementary Figure 1) from paired blood and CSF samples of thirty-two adults with proven ABM prior to antibiotic administration (PM n=28, MM n=4). Using DESeq2, we tested for differential gene expression in CSF and blood. Although the number of MM samples were limited, the results show that differentially expressed genes between PM and MM were more marked in CSF than in blood (S. Figure   4A&B ). Differentially expressed genes were tested for weighted correlation networks using XGR, co-correlated genes were then analysed by network centrality analysis using Gephi. Upregulated genes in in MM centered around genes coding for neutrophil recruitment (CXCL8, CD44, PIK3CG), endothelial activation (VAS3, PTGS2) and cellular signalling and proliferation (KRAS, CASR) (S. Figure 4C ). In contrast, upregulated genes in PM centred around cellular transcriptional (HRAS, ABCC1, RAD50) metabolic (SUCLA2, FASN, NME3) and non-specific inflammatory processes (S. Figure 4D ).
Discussion
We report strikingly different acute inflammatory responses in CSF between meningitis due to the two common community-acquired pathogens S.pneumoniae and N.meningitidis in predominately HIV-1 infected adults in Malawi. Patients with PM, paradoxically, had significant blunting of CSF white cell counts CSF compared to patients with MM, but a contrastingly more intense pro-inflammatory cytokine response, irrespective of HIV-1 serostatus. Although the host-pathogen interaction in the immunologically protected CSF space in ABM is well-recognised to be highly pro-inflammatory [15] , our study documents differing inflammatory responses that are likely to require different anti-inflammatory approaches to improve clinical outcomes. Thus, our study has important implications for the development of better adjuncts to antibiotics in our setting.
Patients with PM in our study had CSF WCC that were 84% lower and were 8 times more likely to die than patients with MM. Whilst low CSF WCC are universally associated with poor outcomes from ABM, [7, 12] our study is the first to describe such a significant difference in CSF cell counts between these two common causes of ABM in a LMIC setting. The underlying mechanisms causing CSF leukopaenia in ABM are poorly understood. In animal models, neutrophil destruction by Although CSF pro-inflammatory cytokines were higher in PM, however the absence of reported correlation between CSF WCC and cytokines in either PM or MM was surprising. In animal models of PM, blocking neutrophil migration to the CSF compartment reduces CSF cytokine production, suggesting neutrophils produce proinflammatory cytokines in CSF [31, 32] . In our patients, we hypothese that these proteins may either be released from necrotic, and thus uncounted leukocytes in the CSF, or from innate neuronal cells such as microglia as opposed to neutrophils alone [27, 33, 34] . Further studies to investigate the cellular source of CSF cytokines in-vivo in both PM and MM are required.
Most of our patients were HIV-1 co-infected, interestingly neither outcome nor CSF WCC differed between those with or without HIV co-infection. HIV is a wellrecognised risk factor for acquisition of both PM and MM [35, 36] . However, HIV appears to have little impact on the established inflammatory response in either infection, although the proportion of HIV-negative patients was relatively small. HIV-1
is not associated with clinical outcome from PM, although it may be a risk factor for mortality in MM [7, 37, 38] . We conclude that high CFR from ABM in our setting is not strongly associated with HIV-1.
Our study was limited by lack of stratification of the inflammatory profiles by bacterial load, CD4 count and HIV-1 viral load; these data were not routinely collected during the clinical trials. Similarly, the CSF cytokine data were limited by the volume of CSF available in some cases. CSF transcriptome data were only available for 2 patients with MM, so although we reported significant differential gene expression in CSF, these results must be considered preliminary. Furthermore, we could not stratify the transcriptome results by neutrophil count. Finally, the data were obtained from patients in a high disease burden, low income setting with high HIV prevalence, and may not be generalisable to other settings.
In summary, our study demonstrates that despite higher CSF pro-inflammatory expressed genes in CSF using XGR, analysed by network centrality using Gephi. TAF1C   TBX21   TCF3   TCN2   THTPA   TK1   TM ED9   TNFSF12   TNNT1   TOP2 A   TPCN1   TRBC1   TTYH2   TTYH3   UAP1L1   UCK1   UROD   VAMP8   WDR5   WDR77   ZDHHC8 S.pneumoniae n=28 N.meningitidis n=4 S.pneumoniae n=13 N.meningitidis n=2 
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